-
Oct 29, 2024 | 
targetedonc.com | Stephen Ansell
Stephen M. Ansell, MD, PhD, chair of the Division of Hematology at Mayo Clinic in Rochester, Minnesota, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma. Additionally, he explains how the treatment for these patients is becoming more personalized.
-
Oct 8, 2024 | 
nature.com | Melissa Hopper |Abigail R. Dropik |Janek S. Walker |Jordan E. Krull |Matthew J. Maurer |Zhi-Zhang Yang | +4 more
AbstractThis study sheds light on the pivotal role of the oncoprotein DEK in B-cell lymphoma. We reveal DEK expression correlates with increased tumor proliferation and inferior overall survival in cases diagnosed with low-grade B-cell lymphoma (LGBCL). We also found significant correlation between DEK expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration.
-
Sep 17, 2024 | 
targetedonc.com | Stephen Ansell
Stephen M. Ansell, MD, PhD, chair of the Division of Hematology at Mayo Clinic in Rochester, Minnesota, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology (SOHO) Annual Meeting in the advanced stage Hodgkin lymphoma space. Here, Ansell highlights additional discussions from the meeting that are of particular interest to a community oncologist, including how to incorporate immunotherapies in the treatment of patients with lymphomas.
-
Sep 7, 2024 | 
onlinelibrary.wiley.com | Stephen Ansell
1 DISEASE OVERVIEW Hodgkin lymphoma (HL) affects ~8570 new patients in the United States each year.1 The disease has a bimodal distribution with an increased incidence in young adults and in patients 55 years and older.2, 3 There are no clearly defined risk factors for the development of this disease and the cause of HL remains unknown.
-
Aug 28, 2024 | 
nature.com | Saurabh Zanwar |Jonas Paludo |Ronald S. Go |Joselle M. Cook |Sikander Ailawadhi |Thomas M Habermann | +10 more
An under-recognized source of bleeding in Waldenström macroglobulinemia (WM) is the development of an acquired von Willebrand syndrome (AVWS) [1]. In WM, the von Willebrand Factor (vWF) glycoprotein can be degraded due to autoantibody destruction, increased shear stress due to hyperviscosity, or sequestered due to adsorption onto malignant cells, leading to the development of AVWS (AVWS-WM) [1, 2].
-
Aug 11, 2024 | 
nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more
Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].
-
Aug 9, 2024 | 
mdpi.com | Luis F. Porrata |Stephen Ansell |Ivana N. Micallef |Patrick Johnston
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jun 19, 2024 | 
nature.com | Melissa Hopper |Jordan E. Krull |C. Chris Huang |Matthew J. Maurer |Susan L Slager |Patrizia Mondello | +8 more
AbstractRecent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq.
-
Jan 31, 2024 | 
healio.com | Stephen Ansell |Cory Perla |Mindy Valcarcel
Read more You've successfully added Hematology Oncology: Lymphoma to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Stephen M. Ansell, MD, PhD, discusses research presented at ASH Annual Meeting and Exposition on circulating tumor DNA.
-
Jan 25, 2024 | 
healio.com | Stephen Ansell |Cory Perla |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Stephen M. Ansell, MD, PhD, discusses research on the durability of bispecific antibodies, presented at ASH Annual Meeting and Exposition.
